{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:14:00Z","timestamp":1778836440907,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["1401-4-73-24841"],"award-info":[{"award-number":["1401-4-73-24841"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Microbes and New Infections"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.nmni.2024.101435","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T11:39:49Z","timestamp":1715859589000},"page":"101435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The effect of polyclonal and monoclonal based antibodies as promising potential therapy for treatment of sepsis: A systematic review"],"prefix":"10.1016","volume":"60-61","author":[{"given":"Marzie","family":"Mahdizade Ari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Esmaeil","family":"Amini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Sholeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3564-9566","authenticated-orcid":false,"given":"Abed","family":"Zahedi Bialvaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10219","key":"10.1016\/j.nmni.2024.101435_bib1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.nmni.2024.101435_bib2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis","volume":"39","author":"Chousterman","year":"2017","journal-title":"Semin Immunopathol"},{"issue":"11","key":"10.1016\/j.nmni.2024.101435_bib3","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.immuni.2021.10.012","article-title":"The immunology of sepsis","volume":"54","author":"van der Poll","year":"2021","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.nmni.2024.101435_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterile inflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.nmni.2024.101435_bib5","first-page":"573","article-title":"Sepsis and Septic Shock \u2013 basics of diagnosis, pathophysiology and clinical decision making","volume":"104","author":"Font","year":"2020","journal-title":"Med Clin"},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030765","article-title":"Recent advances in monoclonal antibody-based approaches in the management of bacterial sepsis","volume":"11","author":"Kharga","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.nmni.2024.101435_bib7","unstructured":"https:\/\/www.cdc.gov\/sepsis\/diagnosis\/index.html."},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.21037\/jtd.2020.01.47","article-title":"An approach to antibiotic treatment in patients with sepsis","volume":"12","author":"Mart\u00ednez","year":"2020","journal-title":"J Thorac Dis"},{"issue":"4","key":"10.1016\/j.nmni.2024.101435_bib9","article-title":"Antibiotic resistance and its impact on disease management","volume":"15","author":"Nadgir","year":"2023","journal-title":"Cureus"},{"issue":"15","key":"10.1016\/j.nmni.2024.101435_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155543","article-title":"Use of intravenous immunoglobulins in sepsis therapy-A clinical view","volume":"21","author":"Jarczak","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1272\/jnms.JNMS.2020_87-303","article-title":"Intravenous immunoglobulin attenuates cecum ligation and puncture-induced acute lung injury by inhibiting apoptosis of alveolar epithelial cells","volume":"87","author":"Hagiwara","year":"2020","journal-title":"J Nippon Med School = Nippon Ika Daigaku zasshi"},{"issue":"8","key":"10.1016\/j.nmni.2024.101435_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081861","article-title":"Recent progress in the discovery and development of monoclonal antibodies against viral infections","volume":"10","author":"Mokhtary","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.nmni.2024.101435_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1166490","article-title":"Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: a systematic review and network meta-analysis","volume":"14","author":"Aungsumart","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmni.2024.101435_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/BTT.S37509","article-title":"Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors","volume":"8","author":"Tanaka","year":"2014","journal-title":"Biol Targets & Ther"},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030654","article-title":"Impact of pharmacokinetic and pharmacodynamic properties of monoclonal antibodies in the management of psoriasis","volume":"14","author":"Rodr\u00edguez-Fern\u00e1ndez","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.nmni.2024.101435_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2022.06.019","article-title":"Beneficial and harmful effects of monoclonal antibodies for the treatment and prophylaxis of COVID-19: systematic review and meta-analysis","volume":"135","author":"Hernandez","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.nmni.2024.101435_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.835677","article-title":"The use of antibody-antibiotic conjugates to fight bacterial infections","volume":"13","author":"Cavaco","year":"2022","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.nmni.2024.101435_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.nmni.2024.101435_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"11","key":"10.1016\/j.nmni.2024.101435_bib21","first-page":"787","article-title":"Anti-endotoxin in the treatment of severe surgical septic shock. Results of a randomized double-blind trial","volume":"68","author":"Aitchison","year":"1985","journal-title":"South Afr Med J = Suid-Afrikaanse tydskrif vir geneeskunde"},{"issue":"2","key":"10.1016\/j.nmni.2024.101435_bib22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.CCM.0000045564.51812.3F","article-title":"Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis","volume":"31","author":"Albertson","year":"2003","journal-title":"Crit Care Med"},{"issue":"13","key":"10.1016\/j.nmni.2024.101435_bib23","first-page":"1723","article-title":"E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial","volume":"283","author":"Angus","year":"2000","journal-title":"E5 Stud Investigat Jama"},{"issue":"7","key":"10.1016\/j.nmni.2024.101435_bib24","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s001340100973","article-title":"A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome","volume":"27","author":"Gallagher","year":"2001","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.nmni.2024.101435_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024475","volume":"9","author":"Geven","year":"2019","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.nmni.2024.101435_bib26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.1991.03470080067031","article-title":"A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group","volume":"266","author":"Greenman","year":"1991","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.nmni.2024.101435_bib27","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.CCM.0000215452.84291.C6","article-title":"IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial","volume":"34","author":"Hentrich","year":"2006","journal-title":"Crit Care Med"},{"issue":"11","key":"10.1016\/j.nmni.2024.101435_bib28","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00134-021-06537-5","article-title":"Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial","volume":"47","author":"Laterre","year":"2021","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1016\/j.nmni.2024.101435_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0883-9441(95)90007-1","article-title":"The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody","volume":"10","author":"Linden","year":"1995","journal-title":"J Crit Care"},{"issue":"1","key":"10.1016\/j.nmni.2024.101435_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-121-1-199407010-00001","article-title":"Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group","volume":"121","author":"McCloskey","year":"1994","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.nmni.2024.101435_bib31","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/00003246-200104000-00015","article-title":"Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES Study","volume":"29","author":"Reinhart","year":"2001","journal-title":"Crit Care Med"},{"issue":"9","key":"10.1016\/j.nmni.2024.101435_bib32","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/00003246-199109000-00003","article-title":"Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial","volume":"19","author":"Schedel","year":"1991","journal-title":"Crit Care Med"},{"issue":"7","key":"10.1016\/j.nmni.2024.101435_bib33","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJM199102143240701","article-title":"Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group","volume":"324","author":"Ziegler","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.nmni.2024.101435_bib34","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/515184","article-title":"Trial EPMSS. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock","volume":"28","author":"Derkx","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.nmni.2024.101435_bib35","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.21037\/apm-21-3694","article-title":"Effects of low-dose intravenous immunoglobulin as the adjunctive therapy in septic shock patients with and without hypogammaglobulinemia: a retrospective cohort study","volume":"11","author":"Goto","year":"2022","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.nmni.2024.101435_bib36","article-title":"Efficacy of an IgM preparation in the treatment of patients with sepsis: a double-blind randomized clinical trial in a pediatric intensive care unit","volume":"1","author":"Elmira","year":"2015","journal-title":"South Eastern Eur J Publ Health"},{"issue":"13","key":"10.1016\/j.nmni.2024.101435_bib37","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2217\/bmm-2020-0204","article-title":"Study of usefulness of low-dose IgG for patients with septic disseminated intravascular coagulation","volume":"14","author":"Takahashi","year":"2020","journal-title":"Biomarkers Med"},{"issue":"10","key":"10.1016\/j.nmni.2024.101435_bib38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0033-1363771","article-title":"Role of pentoxifylline and\/or IgM-enriched intravenous immunoglobulin in the management of neonatal sepsis","volume":"31","author":"Akdag","year":"2014","journal-title":"Am J Perinatol"},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3233\/NPM-190259","article-title":"Prolonged intravenous immunoglobulin treatment in very low birth weight infants with late onset sepsis","volume":"13","author":"Bancalari","year":"2020","journal-title":"J Neonatal Perinat Med"},{"key":"10.1016\/j.nmni.2024.101435_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2393-8-52","article-title":"International Neonatal Immunotherapy Study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial","volume":"8","author":"The","year":"2008","journal-title":"BMC Pregnancy Childbirth"},{"issue":"13","key":"10.1016\/j.nmni.2024.101435_bib41","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1100441","article-title":"Treatment of neonatal sepsis with intravenous immune globulin","volume":"365","author":"Brocklehurst","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nmni.2024.101435_bib42","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1365-2249.1995.tb08359.x","article-title":"Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis","volume":"101","author":"Haque","year":"1995","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"10.1016\/j.nmni.2024.101435_bib43","first-page":"1113","article-title":"Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis","volume":"36","author":"Shenoi","year":"1999","journal-title":"Indian Pediatr"},{"issue":"2","key":"10.1016\/j.nmni.2024.101435_bib44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1542\/peds.2010-3081","article-title":"A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis","volume":"128","author":"Weisman","year":"2011","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.nmni.2024.101435_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036616","article-title":"Adjunctive IgM-enriched immunoglobulin therapy with a personalised dose based on serum IgM-titres versus standard dose in the treatment of septic shock: a randomised controlled trial (IgM-fat trial)","volume":"11","author":"Biagioni","year":"2021","journal-title":"BMJ Open"},{"issue":"Suppl 2","key":"10.1016\/j.nmni.2024.101435_bib46","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1007\/BF01644200","article-title":"[Antibody to lipoid A in the treatment of septic shock]","volume":"15","author":"Jaspers","year":"1987","journal-title":"Infection"},{"issue":"5","key":"10.1016\/j.nmni.2024.101435_bib47","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4103\/ijp.ijp_881_20","article-title":"Pentaglobin (immunoglobulin M-enriched immunoglobulin) as adjuvant therapy for premature and very low-birth-weight neonates with sepsis","volume":"53","author":"Nassir","year":"2021","journal-title":"Indian J Pharmacol"},{"issue":"5","key":"10.1016\/j.nmni.2024.101435_bib48","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10156-013-0612-y","article-title":"A Phase II study of polyclonal anti-TNF-\u03b1 (AZD9773) in Japanese patients with severe sepsis and\/or septic shock","volume":"19","author":"Aikawa","year":"2013","journal-title":"J Infect Chemother : Off J Japan Soc Chemother"},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib49","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/CCM.0000000000000043","article-title":"Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-\u03b1 fragment antibody AZD9773 in adult patients with severe sepsis and\/or septic shock: randomized, double-blind, placebo-controlled phase IIb study","volume":"42","author":"Bernard","year":"2014","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.nmni.2024.101435_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13613-019-0609-5","article-title":"IgM-enriched immunoglobulins (Pentaglobin) may improve the microcirculation in sepsis: a pilot randomized trial","volume":"9","author":"Domizi","year":"2019","journal-title":"Ann Intensive Care"},{"issue":"1","key":"10.1016\/j.nmni.2024.101435_bib51","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc11203","article-title":"A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics\/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock","volume":"16","author":"Morris","year":"2012","journal-title":"Crit Care"},{"issue":"9","key":"10.1016\/j.nmni.2024.101435_bib52","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/01.CCM.0000230385.82679.34","article-title":"Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis","volume":"34","author":"Rice","year":"2006","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib53","doi-asserted-by":"crossref","first-page":"F182","DOI":"10.1136\/fn.70.3.F182","article-title":"Effect of fresh frozen plasma and gammaglobulin on humoral immunity in neonatal sepsis","volume":"70","author":"Acunas","year":"1994","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"9","key":"10.1016\/j.nmni.2024.101435_bib54","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/00003246-199609000-00002","article-title":"INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group","volume":"24","author":"Cohen","year":"1996","journal-title":"Crit Care Med"},{"key":"10.1016\/j.nmni.2024.101435_bib55","first-page":"28","article-title":"Role of immunoglobulins in neonatal sepsis","volume":"11","author":"Capasso","year":"2015","journal-title":"Translation Med @ UniSa"},{"issue":"12","key":"10.1016\/j.nmni.2024.101435_bib56","first-page":"1293","article-title":"IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis","volume":"142","author":"Haque","year":"1960","journal-title":"Am J Dis Child"},{"issue":"1","key":"10.1016\/j.nmni.2024.101435_bib57","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1086\/315214","article-title":"Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options","volume":"181","author":"Gogos","year":"2000","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.nmni.2024.101435_bib58","first-page":"525","article-title":"Perioperative TNF alpha and IL-6 concentrations correlate with septic state, organ function, and Apache II scores in intra-abdominal infection","volume":"159","author":"F\u00fcgger","year":"1993","journal-title":"Eur J Surg= Acta Chirurgica"},{"issue":"9","key":"10.1016\/j.nmni.2024.101435_bib59","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1164\/rccm.200204-302OC","article-title":"Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis","volume":"166","author":"Eichacker","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7326\/0003-4819-113-3-227","article-title":"Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy","volume":"113","author":"Parrillo","year":"1990","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.nmni.2024.101435_bib61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1086\/375593","article-title":"Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)","volume":"37","author":"Opal","year":"2003","journal-title":"Clin Infect Dis : Off Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.nmni.2024.101435_bib62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4161\/viru.27024","article-title":"Gram-positive and gram-negative bacterial toxins in sepsis: a brief review","volume":"5","author":"Ramachandran","year":"2014","journal-title":"Virulence"},{"issue":"20","key":"10.1016\/j.nmni.2024.101435_bib63","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.1073\/pnas.0701821104","article-title":"Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureus","volume":"104","author":"Gr\u00fcndling","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.nmni.2024.101435_bib64","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.imlet.2008.03.009","article-title":"Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells","volume":"118","author":"Kimbrell","year":"2008","journal-title":"Immunol Lett"},{"issue":"20","key":"10.1016\/j.nmni.2024.101435_bib65","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJM198211113072001","article-title":"Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli","volume":"307","author":"Ziegler","year":"1982","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.nmni.2024.101435_bib66","first-page":"781","article-title":"The effects of immune globulin on endotoxemia","volume":"14","author":"Endo","year":"1992","journal-title":"Clin Therapeut"},{"issue":"4","key":"10.1016\/j.nmni.2024.101435_bib67","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1365-2958.1997.6251991.x","article-title":"The exoenzyme S regulon of Pseudomonas aeruginosa","volume":"26","author":"Frank","year":"1997","journal-title":"Mol Microbiol"},{"issue":"10","key":"10.1016\/j.nmni.2024.101435_bib68","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s001340000648","article-title":"Ventilator-induced lung injury leads to loss of alveolar and systemic compartmentalization of tumor necrosis factor-alpha","volume":"26","author":"Haitsma","year":"2000","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1016\/j.nmni.2024.101435_bib69","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/BF00542410","article-title":"Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication","volume":"30","author":"Schaumann","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.nmni.2024.101435_bib70","first-page":"770","article-title":"Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock","volume":"28","author":"Derkx","year":"1999","journal-title":"Eur Pediatr Meningococ Septic Shock Trial Stud Group. Clin Infect Dis : Off Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.nmni.2024.101435_bib71","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.PCC.0000149131.72248.E6","article-title":"International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics","volume":"6","author":"Goldstein","year":"2005","journal-title":"Pediatr Crit Care Med : J Soc Critic Care Med World Federat Pediatr Intens Critic Care Soc"},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib72","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/mp.53.3.111","article-title":"Monoclonal antibodies","volume":"53","author":"Nelson","year":"2000","journal-title":"Mol Pathol : Materialpr\u00fcfung"},{"issue":"6","key":"10.1016\/j.nmni.2024.101435_bib73","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2796.2006.01726.x","article-title":"Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis","volume":"260","author":"Norrby-Teglund","year":"2006","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.nmni.2024.101435_bib74","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-2249.2005.02779.x","article-title":"Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells","volume":"140","author":"Olas","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nmni.2024.101435_bib75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fimmu.2015.00004","article-title":"Intravenous immunoglobulin and immunomodulation of B-cell - in vitro and in vivo effects","volume":"6","author":"Mitrevski","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmni.2024.101435_bib76","doi-asserted-by":"crossref","first-page":"84","DOI":"10.33192\/Smj.2021.12","article-title":"Comparison of adjunctive treatment with IgMEnriched IVIG and antibiotics alone in treatment of neonatal sepsis","volume":"72","author":"Boonsopa","year":"2021","journal-title":"Siriraj Med J"}],"container-title":["New Microbes and New Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297524002191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297524002191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:45:56Z","timestamp":1778834756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2052297524002191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":76,"alternative-id":["S2052297524002191"],"URL":"https:\/\/doi.org\/10.1016\/j.nmni.2024.101435","relation":{},"ISSN":["2052-2975"],"issn-type":[{"value":"2052-2975","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of polyclonal and monoclonal based antibodies as promising potential therapy for treatment of sepsis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"New Microbes and New Infections","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmni.2024.101435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101435"}}